Arrowhead Pharmaceuticals: Recent Developments and Upcoming Webinar
Arrowhead Pharmaceuticals Discontinues Cardiovascular Candidate, Focuses on Obesity and Metabolism
A month after discontinuing its Phase II cardiovascular candidate, Arrowhead Pharmaceuticals has shifted its focus towards obesity and metabolism.
Upcoming Obesity and Metabolism Webinar
The company will host a webinar on obesity and metabolism today, August 14, 2024, at 2:00 PM ET, as part of its research and development efforts.
Positive Preclinical Results for ARO-INHBE
Arrowhead Pharmaceuticals has announced positive preclinical data for ARO-INHBE, a potential treatment for non-alcoholic steatohepatitis (NASH).
Key Findings from Preclinical Studies
- ARO-INHBE significantly reduced hepatic inflammation in animal models.
- The compound improved liver function and reduced fibrosis.
- ARO-INHBE demonstrated a favorable safety profile.
These findings suggest that ARO-INHBE has the potential to be an effective treatment for NASH, a serious liver disease that can lead to cirrhosis and liver failure.
Company Overview
Arrowhead Pharmaceuticals is a Pasadena, California-based company focused on developing RNA interference (RNAi) therapeutics. RNAi is a natural process that regulates gene expression, and Arrowhead's technology allows scientists to harness this process to develop new treatments for a wide range of diseases.
Comments